Qiyu Bio

启愈生物

Qiyu Bio

Other

Qiyu Bio develops innovative large-molecule biologics for difficult-to-treat cancers, autoimmune diseases, and other conditions in China and globally. Its technology platforms include phage display, hybridoma antibody humanization, single-domain antibodies, and antibody engineering.

Latest round: Series C (2025)

Source: ChinaBulls — chinabulls.com

Last updated 2025-06-01